Innovent's bispecific antibody, IBI363, enters a global phase 3 trial for IO-resistant lung cancer, the first of its kind, ...

Biogen (($CC:HTER)) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) is currently conducting a Phase ...

NCX 470 met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline compared to the standard of care, latanoprost 0.005%.

Despite being a rare disease impacting less than a million people worldwide, gMG treatment is an increasingly crowded market, ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. In a significant advancement for cancer ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

In 2021, ATYR completed a phase 1b/2a trial in pulmonary sarcoidosis, and have since started a phase 3 trial. Currently the ...

NCX 470 0.1%, a novel nitric oxide-donating bimatoprost eye drop, achieved its primary endpoint in the phase 3 Denali ...

In this video, Yasha S. Modi, MD, discusses end-of-study results for EYP-1901 from EyePoint Pharmaceuticals, a bioerodible, sustained-release intravitreal insert to deliver vorolanib for diabetic ...

AbbVie on Thursday said the Phase 3 study evaluating the safety and efficacy of Rinvoq in patients with severe forms of the disease that causes sudden hair loss met its primary endpoint of 80% or more ...

IO Biotech's phase 3 melanoma trial showed a strong PFS benefit, especially in true 1st-line and PD1-negative patients. Click ...